FDA Scolds Teva Pharmaceutical Industries Limited for an Unbalanced and Overblown Handout

Published: Apr 23, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

File this under ‘how could they not know?’ Drugmakers are well aware of the requirements for readying promotional materials, steps that include submitting a form to spell out the messages to be conveyed. Teva Pharmaceuticals, however, was tagged earlier this month by the FDA for preparing a physician handout for its Clozapine schizophrenia medication that was sorely lacking – risks were minimized and various unsubstantiated claims were made. In an April 8 untitled letter, the FDA took the drugmaker to task because the article implied Clozapine demonstrated significant efficacy in treating four of five symptom clusters – excitement, positive, cognitive, and depression/anxiety, as well as specific symptoms of excitement - as well as superiority to other meds.

Help employers find you! Check out all the jobs and post your resume.

Back to news